Over 750,000 Americans have End Stage Renal Disease, also known as kidney failure. Around 500,000 are on dialysis, while the rest have a kidney transplant. When a patient is prescribed dialysis, they visit a dialysis center 3-5 times weekly for 4-5 hours a time, sitting in a chair unable to move.

patient helped during dialysis session in hospitalpatient helped during dialysis session in hospitalpatient helped during dialysis session in hospitalpatient helped during dialysis session in hospital

Dialysis patients want freedom to travel,
work full time jobs, and maintain a daily routine
not overshadowed by their dialysis treatments.

Dialysis hasn’t changed much in the last few decades. Unlike those with other chronic diseases that have seen both technological and pharmaceutical innovation, individuals with Chronic Kidney Disease have been left behind.

We expect wearable dialysis to democratize the home dialysis space. Currently, patients are required to implement expensive plumbing and electrical upgrades prior to being able to receive dialysis at home. Wearable dialysis eliminates these barriers. This also opens the opportunity for global expansion into countries most impacted by kidney disease such as Mexico, India, and other areas.

Reimagining Dialysis with Project Nephron
a wearable artificial kidney for the 21st century

The dialysis space is in need of innovation, with patients currently forced to spend 3 days a week (4 hours per treatment) receiving dialysis from a stationary machine. With dialysis patients on the rise, mainly due to risks of diabetes and hypertension, the worldwide global dialysis equipment market is projected to reach a worth of ~$23B by 2028.

Project Nephron is a culmination of years of research by our interdisciplinary team. We are addressing the many challenges of wearable dialysis such as fluid  management, needle safety, and dialysate regeneration. Project Nephron will provide dialysis patients with the  same technological innovations that many other chronic diseases (such as diabetes) have received in wearable, connected therapy that fits a patient’s life. 

The average US annual expense per dialysis patient is $87,000. Our device is designed to match the performance of traditional hemodialysis machines, within a low profile and lightweight wearable device. At a cost targeted to be significantly below that of current hemodialysis machines, we are presenting a significant opportunity to capture market share and contribute to healthcare equity.

Dialysis doesn’t require a bulky machine
to be done effectively



Project Nephron commercially available


BioRema 26H cartridge is available for sale in Canada


Founded NephriaBio